Advertisement

Declining mortality from adult pneumococcal infections linked to children's vaccination

Published:February 13, 2016DOI:https://doi.org/10.1016/j.jinf.2016.01.011

      Highlights

      • The use of PCVs for children has been associated with a decrease of adult invasive pneumococcal disease (IPD) rates by the effect of herd protection.
      • PCV7 serotypes were associated with high case fatality rate in adults with IPD.
      • An additional indirect benefit of paediatric PCV was a decline in adult IPD mortality linked to a decrease of PCV7 serotypes-specific death.

      Summary

      Objective

      To determine changes in mortality among adults with invasive pneumococcal disease (IPD) after introducing pneumococcal conjugate vaccines (PCVs) in children.

      Methods

      An active surveillance of adults with culture-proven IPD in Barcelona. Serotype-specific mortality and rates of disease and death were analysed in three periods: baseline (1994–2001), PCV7 (2002–2009) and PCV13 (2010–2013).

      Results

      Overall, IPD caused by PCV7 serotypes was associated with increased case fatality rate (24 percent).
      In patients 18–64 years (baseline vs. PCV7 vs. PCV13 periods), case fatality rate from IPD decreased (22 vs.14 vs. 12 percent), and it was associated with a decline in PCV7 serotypes (3.56 vs. 2.80 vs. 1.49 cases/105 person-years) and in PCV7 serotypes-specific death (0.74 vs. 0.53 vs. 0.09 deaths/105 person-years).
      In patients ≥65 years, case fatality rate did not change (24 vs. 22 vs. 24 percent); however, there was a decline in PCV7 serotypes-specific death (4.94 vs. 3.58 vs. 2.45 deaths/105 person-years), and an increase in non-PCV serotypes-specific death (2.55 vs. 3.70 vs. 4.09 deaths/105 person-years).

      Conclusions

      The use of PCVs for children was associated with a reduction of mortality from IPD in adults 18–64 years, through the indirect effect of herd protection. In older adults, age-related factors could play a role in IPD mortality.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Regev-Yochay G.
        • Raz M.
        • Dagan R.
        • Porat N.
        • Shainberg B.
        • Pinco E.
        • et al.
        Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings.
        Clin Infect Dis. 2004 Mar 1; 38: 632-639
        • Bogaert D.
        • De Groot R.
        • Hermans P.W.
        Streptococcus pneumoniae colonisation: the key to pneumococcal disease.
        Lancet Infect Dis. 2004 Mar; 4: 144-154
        • Grau I.
        • Ardanuy C.
        • Calatayud L.
        • Rolo D.
        • Domenech A.
        • Liñares J.
        • et al.
        Invasive pneumococcal disease in healthy adults: increase of empyema associated with the clonal-type Sweden1-ST306.
        PLoS One. 2012; 7: e42595
        • Kyaw M.H.
        • Rose Jr., C.E.
        • Fry A.M.
        • Singleton J.A.
        • Moore Z.
        • Zell E.R.
        • et al.
        The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults.
        J Infect Dis. 2005; 192: 377-386
        • Klemets P.
        • Lyytikäinen O.
        • Ruutu P.
        • Ollgren J.
        • Nuorti J.P.
        Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies.
        BMC Infect Dis. 2008 Jul 22; 8: 96
        • Grau I.
        • Pallares R.
        • Tubau F.
        • Schulze M.H.
        • Llopis F.
        • Podzamczer D.
        • et al.
        Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
        Arch Intern Med. 2005; 165: 1533-1540
        • van Hoek A.J.
        • Andrews N.
        • Waight P.A.
        • Stowe J.
        • Gates P.
        • George R.
        • et al.
        The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England.
        J Infect. 2012; 65: 17-24
        • Horácio A.N.
        • Lopes J.P.
        • Ramirez M.
        • Melo-Cristino J.
        • Portuguese Group for the Study of Streptococcal Infections
        Non-invasive pneumococcal pneumonia in Portugal – serotype distribution and antimicrobial resistance.
        PLoS One. 2014 Jul 30; 9: e103092
        • Brueggemann A.B.
        • Griffiths D.T.
        • Meats E.
        • Peto T.
        • Crook D.W.
        • Spratt B.G.
        Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential.
        J Infect Dis. 2003 May 1; 187: 1424-1432
        • Sjöstrom K.
        • Spindler C.
        • Örqvist A.
        • Kalin M.
        • Sandgren A.
        • Kühlmann-Berenzon K.
        • et al.
        Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen.
        Clin Infect Dis. 2006; 42: 451-459
        • Hausdorff W.P.
        • Feikin D.R.
        • Klugman K.P.
        Epidemiological differences among pneumococcal serotypes.
        Lancet Infect Dis. 2005; 5: 83-93
        • Whitney C.G.
        • Farley M.M.
        • Hadler J.
        • Harrison L.H.
        • Bennett N.M.
        • Lynfield R.
        • et al.
        Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.
        N Engl J Med. 2003 May 1; 348: 1737-1746
        • Lexau C.A.
        • Lynfield R.
        • Danila R.
        • Pilishvili T.
        • Facklam R.
        • Farley M.M.
        • et al.
        Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.
        JAMA. 2005; 294: 2043-2051
        • von Gottberg A.
        • de Gouveia L.
        • Tempia S.
        • Quan V.
        • Meiring S.
        • von Mollendorf C.
        • et al.
        GERMS-SA Investigators. Effects of vaccination on invasive pneumococcal disease in South Africa.
        N Engl J Med. 2014 Nov 13; 371: 1889-1899
        • Moore M.R.
        • Link-Gelles R.
        • Schaffner W.
        • Lynfield R.
        • Lexau C.
        • Bennett N.M.
        • et al.
        Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
        Lancet Infect Dis. 2015 Mar; 15: 301-309
        • Waight P.A.
        • Andrews N.J.
        • Ladhani S.N.
        • Sheppard C.L.
        • Slack M.P.
        • Miller E.
        Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
        Lancet Infect Dis. 2015 May; 15: 535-543
        • Trampuz A.
        • Widmer A.F.
        • Fluckiger U.
        • Haenggi M.
        • Frei R.
        • Zimmerli W.
        Changes in the epidemiology of pneumococcal bacteremia in a Swiss university hospital during a 15-year period, 1986–2000.
        Mayo Clin Proc. 2004 May; 79: 604-612
        • Pallares R.
        • Liñares J.
        • Vadillo M.
        • Cabellos C.
        • Manresa F.
        • Viladrich P.F.
        • et al.
        Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.
        N Engl J Med. 1995 Aug 24; 333: 474-480
        • Harboe Z.B.
        • Thomsen R.W.
        • Riis A.
        • Valentiner-Branth P.
        • Christensen J.J.
        • Lambertsen L.
        • et al.
        Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study.
        PLoS Med. 2009 May 26; 6: e1000081https://doi.org/10.1371/journal.pmed.1000081
        • Martens P.
        • Worm S.W.
        • Lundgren B.
        • Konradsen H.B.
        • Benfield T.
        Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited.
        BMC Infect Dis. 2004 Jun 30; 4: 21
        • Alanee S.R.
        • McGee L.
        • Jackson D.
        • Chiou C.C.
        • Feldman C.
        • Morris A.J.
        • et al.
        • International Pneumococcal Study Group
        Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study.
        Clin Infect Dis. 2007 Jul 1; 45: 46-51
        • Weinberger D.M.
        • Harboe Z.B.
        • Sanders E.A.
        • Ndiritu M.
        • Klugman K.P.
        • Rückinger S.
        • et al.
        Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis.
        Clin Infect Dis. 2010 Sep 15; 51: 692-699
        • Garau J.
        • Calbo E.
        Capsular types and predicting patient outcomes in pneumococcal bacteremia.
        Clin Infect Dis. 2007 Jul 1; 45: 52-54
        • Frazão N.
        • Hiller N.L.
        • Powell E.
        • Earl J.
        • Ahmed A.
        • Sá-Leão R.
        • et al.
        Virulence potential and genome-wide characterization of drug resistant Streptococcus pneumoniae clones selected in vivo by the 7-valent pneumococcal conjugate vaccine.
        PLoS One. 2013 Sep 19; 8: e74867
        • McCabe W.R.
        • Jackson G.G.
        Gram-negative bacteremia. Etiology and ecology.
        Arch Intern Med. 1962; 110: 847-855
        • Rolo D.
        • Ardanuy C.
        • Calatayud L.
        • Pallares R.
        • Grau I.
        • García E.
        • et al.
        Characterization of invasive pneumococci of serogroup 6 from adults in Barcelona, Spain, in 1994 to 2008.
        J Clin Microbiol. 2011 Jun; 49: 2328-2330
        • Clinical Laboratory Standard Institute
        Performance standards for antimicrobial susceptibility testing; twenty-fourth informational suplement.
        (CLSI document M100–S24) Clinical and Laboratory Standards Institute, Wayne, PA2014
        • De Carvalho Gomes H.
        • Muscat M.
        • Monnet D.L.
        • Giesecke J.
        • Lopalco P.L.
        Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001–2007.
        Euro Surveill. 2009 Mar 26; 14 (pii: 19159)
        • Ciruela P.
        • Soldevila N.
        • Hernández S.
        • Selva L.
        • de Sevilla M.F.
        • García-García J.J.
        • et al.
        Risk factors for invasive pneumococcal disease in a community with a high proportion of non vaccine serotypes.
        Vaccine. 2013 Jan 30; 31: 960-966
        • Henriques B.
        • Kalin M.
        • Ortqvist A.
        • Olsson Liljequist B.
        • Almela M.
        • Marrie T.J.
        • et al.
        Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries.
        J Infect Dis. 2000 Sep; 182: 833-839
      1. Web de l'Estadística Oficial de Catalunya. Institut d'Estadística de Catalunya. Available at: http://www.idescat.net [accessed 07.03.15].

        • Johnstone J.
        • Eurich D.T.
        • Minhas J.K.
        • Marrie T.J.
        • Majumdar S.R.
        Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.
        Clin Infect Dis. 2010 Jul 1; 51: 15-22
        • Rueda A.M.
        • Serpa J.A.
        • Matloobi M.
        • Mushtaq M.
        • Musher D.M.
        The spectrum of invasive pneumococcal disease at an adult tertiary care hospital in the early 21st century.
        Med (Baltimore). 2010 Sep; 89: 331-336
        • Gattarello S.
        • Borgatta B.
        • Solé-Violán J.
        • Vallés J.
        • Vidaur L.
        • Zaragoza R.
        • et al.
        • Community-Acquired Pneumonia en la Unidad de Cuidados Intensivos II Study Investigators
        Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000–2013).
        Chest. 2014 Jul; 146: 22-31
        • Harbarth S.
        • Garbino J.
        • Pugin J.
        • Romand J.A.
        • Pittet D.
        Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis.
        Eur J Clin Microbiol Infect Dis. 2005 Oct; 24: 688-690
        • Chokshi R.
        • Restrepo M.I.
        • Weeratunge N.
        • Frei C.R.
        • Anzueto A.
        • Mortensen E.M.
        Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia.
        Eur J Clin Microbiol Infect Dis. 2007 Jul; 26: 447-451
        • Garin N.
        • Genné D.
        • Carballo S.
        • Chuard C.
        • Eich G.
        • Hugli O.
        • et al.
        β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
        JAMA Intern Med. 2014 Dec; 174: 1894-1901
        • Postma D.F.
        • van Werkhoven C.H.
        • van Elden L.J.
        • Thijsen S.F.
        • Hoepelman A.I.
        • Kluytmans J.A.
        • et al.
        Antibiotic treatment strategies for community-acquired pneumonia in adults.
        N Engl J Med. 2015 Apr 2; 372: 1312-1323
        • Harboe Z.B.
        • Valentiner-Branth P.
        • Benfield T.L.
        • Christensen J.J.
        • Hjuler T.
        • Kaltoft M.
        • et al.
        Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000–2005.
        Vaccine. 2008 Jul 4; 26: 3765-3771
        • Tsigrelis C.
        • Tleyjeh I.M.
        • Lahr B.D.
        • Nyre L.M.
        • Virk A.
        • Baddour L.M.
        Decreases in case-fatality and mortality rates for invasive pneumococcal disease in Olmsted County, Minnesota, during 1995–2007: a population-based study.
        Clin Infect Dis. 2008 Dec 1; 47: 1367-1371
        • van Hoek A.J.
        • Andrews N.
        • Waight P.A.
        • George R.
        • Miller E.
        Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes.
        PLoS One. 2012; 7: e39150https://doi.org/10.1371/journal.pone.0039150
        • Ricketson L.J.
        • Nettel-Aguirre A.
        • Vanderkooi O.G.
        • Laupland K.B.
        • Kellner J.D.
        Factors influencing early and late mortality in adults with invasive pneumococcal disease in Calgary, Canada: a prospective surveillance study.
        PLoS One. 2013 Oct 8; 8: e71924https://doi.org/10.1371/journal.pone.0071924
        • Burgos J.
        • Falcó V.
        • Borrego A.
        • Sordé R.
        • Larrosa M.N.
        • Martinez X.
        • et al.
        Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia.
        Clin Microbiol Infect. 2013 Apr; 19: 385-391
        • Harboe Z.B.
        • Dalby T.
        • Weinberger D.M.
        • Benfield T.
        • Mølbak K.
        • Slotved H.C.
        • et al.
        Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.
        Clin Infect Dis. 2014 Oct 15; 59: 1066-1073
        • Ruiz L.A.
        • Zalacain R.
        • Capelastegui A.
        • Bilbao A.
        • Gomez A.
        • Uranga A.
        • et al.
        Bacteremic pneumococcal pneumonia in elderly and very elderly patients: host- and pathogen-related factors, process of care, and outcome.
        J Gerontol A Biol Sci Med Sci. 2014 Aug; 69 (Epub 2014 Jan 27): 1018-1024https://doi.org/10.1093/gerona/glt288
        • Jansen A.G.
        • Rodenburg G.D.
        • van der Ende A.
        • van Alphen L.
        • Veenhoven R.H.
        • Spanjaard L.
        • et al.
        Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome.
        Clin Infect Dis. 2009 Jul 15; 49: e23-e39
        • Naucler P.
        • Darenberg J.
        • Morfeldt E.
        • Ortqvist A.
        • Henriques Normark B.
        Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia.
        Thorax. 2013 Jun; 68: 571-579
        • Luján M.
        • Burgos J.
        • Gallego M.
        • Falcó V.
        • Bermudo G.
        • Planes A.
        • et al.
        Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies.
        Clin Infect Dis. 2013 Dec; 57: 1722-1730
        • Pulido M.
        • Sorvillo F.
        Declining invasive pneumococcal disease mortality in the United States, 1990–2005.
        Vaccine. 2010 Jan 22; 28: 889-892
        • Vila-Corcoles A.
        • Ochoa-Gondar O.
        Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.
        Drugs Aging. 2013 May; 30: 263-276
        • Tomczyk S.
        • Bennett N.M.
        • Stoecker C.
        • Gierke R.
        • Moore M.N.
        • Whitney C.G.
        • et al.
        Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Morb Mortal Wkly Rep. 2014; 63: 822-825
        • Bonten M.J.
        • Huijts S.M.
        • Bolkenbaas M.
        • Webber C.
        • Patterson S.
        • Gault S.
        • et al.
        Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
        N Engl J Med. 2015 Mar 19; 372: 1114-1125